Ivan Poullaos

Ivan is a nationally recognized patent trial lawyer who helps pharmaceutical innovators, generic and biosimilar manufacturers, and technology‑driven companies solve their most complex IP disputes. With deep experience across the Hatch‑Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA), clients rely on Ivan to quickly distill dense technical records, craft winning trial narratives, and drive efficient, business‑aligned litigation strategies. Chambers USA has recognized Ivan as “an extremely responsive and trial-savvy lawyer.”

Ivan is consistently recognized for excellence in high‑stakes patent litigation, including rankings in Chambers (Intellectual Property – Illinois) and the IAM Patent 1000, which describes him as “an excellent litigator for high‑stakes patent jury cases.” He has secured standout results for clients across the life sciences sector, including:

A significant jury verdict clearing his client’s pharmaceutical product of infringement, defeating a claim for more than $40 million in requested damages.

A landmark trial victory invalidating the patent covering the active ingredient in the hepatitis B drug Baraclude® (entecavir)—the first case to find a new chemical compound claim obvious, a decision later affirmed on appeal.

Complete trial, appellate, and summary judgment wins for a leading cell‑culture device manufacturer facing trade secret, contract, and patent infringement allegations.

With a degree in chemistry and more than two decades in practice, Ivan excels in translating complex scientific and engineering concepts into compelling courtroom advocacy. He regularly represents clients in U.S. district courts, the Federal Circuit, and before the Patent Trial and Appeal Board.